Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation or Pathologic Complete Response After Neoadjuvant Therapy for Rectal Cancer

NCT05629442 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT05629442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05629442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation or Pathologic Complete Response After Neoadjuvant Therapy for Rectal Cancer
Lead sponsor
Massachusetts General Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
June 30, 2030
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non metastatic rectal cancer, rectal cancer